S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
NYSE:ABBV

AbbVie - ABBV Price Target & Analyst Ratings

$134.21
-8.51 (-5.96%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$134.09
$142.33
50-Day Range
$134.21
$151.15
52-Week Range
$106.86
$175.91
Volume
15.36 million shs
Average Volume
5.28 million shs
Market Capitalization
$237.30 billion
P/E Ratio
19.01
Dividend Yield
3.95%
Price Target
$159.35

AbbVie Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 16 Analyst Ratings

Consensus Analyst Price Target

$159.35
18.73% Upside
High Prediction$200.00
Average Prediction$159.35
Low Prediction$135.00
TypeCurrent
10/2/21 to 10/2/22
1 Month Ago
9/2/21 to 9/2/22
3 Months Ago
7/4/21 to 7/4/22
1 Year Ago
10/2/20 to 10/2/21
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
10 Buy rating(s)
12 Buy rating(s)
Hold
6 Hold rating(s)
6 Hold rating(s)
5 Hold rating(s)
1 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$159.35$159.35$159.75$126.33
Predicted Upside18.73% Upside11.32% Upside11.26% Upside14.38% Upside
Get AbbVie Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.


ABBV Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ABBV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

AbbVie Stock vs. The Competition

TypeAbbVieMedical CompaniesS&P 500
Consensus Rating Score
2.50
2.68
2.49
Consensus RatingModerate BuyBuyHold
Predicted Upside18.73% Upside1,099.23% Upside35.94% Upside
News Sentiment RatingNeutral News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
1266
73.60%
Underperform Votes
454
26.40%
Avg. Outperform Votes
166
66.67%
Avg. Underperform Votes
83
33.33%
Avg. Outperform Votes
852
68.43%
Avg. Underperform Votes
393
31.57%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/24/2022Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$165.00 ➝ $155.00+11.49%
8/9/2022Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$160.00+13.77%
8/1/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$191.00 ➝ $188.00+33.96%
8/1/2022UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$154.00 ➝ $146.00+4.03%
8/1/2022Atlantic Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Neutral$178.00 ➝ $162.00+12.88%
7/29/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$160.00 ➝ $155.00+8.16%
5/23/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageUnderperform$140.00-7.29%
5/6/2022Daiwa Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Neutral$150.00-1.43%
5/2/2022Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$165.00 ➝ $200.00+36.17%
4/25/2022BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Gary Nachman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform$161.00 ➝ $174.00+13.31%
4/12/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral$122.00 ➝ $140.00-17.56%
3/1/2022Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$155.00 ➝ $170.00+15.04%
2/4/2022Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$154.00 ➝ $166.00+17.96%
2/3/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$165.00 ➝ $180.00+27.90%
2/3/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral$135.00 ➝ $138.00-0.45%
1/18/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$130.00 ➝ $150.00+10.40%
1/13/2022Redburn Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy
11/24/2021Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Robyn Karnauskas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy$118.00 ➝ $135.00+13.56%
11/23/2021Societe Generale
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
4/7/2021Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated Coverage$135.00+28.94%
11/10/2020Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$120.00+26.16%
9/29/2020Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$98.00+12.28%
6/10/2020Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Joshua Schimmer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$111.00+14.55%
6/9/2020Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradePeer Perform ➝ Outperform
11/1/2019Piper Jaffray Companies
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Christopher Raymond
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Target$81.00 ➝ $90.00+10.09%
(Data available from 10/2/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












ABBV Price Target - Frequently Asked Questions

What is AbbVie's consensus rating and price target?

According to the issued ratings of 16 analysts in the last year, the consensus rating for AbbVie stock is Moderate Buy based on the current 1 sell rating, 6 hold ratings and 9 buy ratings for ABBV. The average twelve-month price prediction for AbbVie is $159.35 with a high price target of $200.00 and a low price target of $135.00. Learn more on ABBV's analyst rating history.

Do Wall Street analysts like AbbVie more than its competitors?

Analysts like AbbVie less than other Medical companies. The consensus rating for AbbVie is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how ABBV compares to other companies.

Do MarketBeat users like AbbVie more than its competitors?

MarketBeat users like AbbVie more than other Medical companies. 73.60% of MarketBeat users gave AbbVie an outperform vote while medical companies recieve an average of 66.67% outperform votes by MarketBeat users.

Does AbbVie's stock price have much upside?

According to analysts, AbbVie's stock has a predicted upside of 11.32% based on their 12-month price targets.

What analysts cover AbbVie?

AbbVie has been rated by Argus, Atlantic Securities, Barclays, Morgan Stanley, Piper Sandler, and UBS Group in the past 90 days.


Stock Ratings Reports and Tools

This page (NYSE:ABBV) was last updated on 10/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.